Sheikh Kashif, Camejo Germán, Lanne Boel, Halvarsson Torbjörn, Landergren Marie Rydén, Oakes Nicholas D
AstraZeneca R&D Cardiovascular/Gastrointestinal, Mölndal, Sweden.
Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1157-65. doi: 10.1152/ajpendo.00254.2006. Epub 2006 Dec 12.
PPARalpha agonists have been characterized largely in terms of their effects on lipids and glucose metabolism, whereas little has been reported about effects on amino acid metabolism. We studied responses to the PPARalpha agonist WY 14,643 (30 micromol x kg(-1) x day(-1) for 4 wk) in rats fed a saturated fat diet. Plasma and urine were analyzed with proton NMR. Plasma amino acids were measured using HPLC, and hepatic gene expression was assessed with DNA arrays. The high-fat diet elevated plasma levels of insulin and triglycerides (TG), and WY 14,643 treatment ameliorated this insulin resistance and dyslipidemia, lowering plasma insulin and TG levels. In addition, treatment decreased body weight gain, without altering cumulative food intake, and increased liver mass. WY 14,643 increased plasma levels of 12 of 22 amino acids, including glucogenic and some ketogenic amino acids, whereas arginine was significantly decreased. There was no alteration in branched-chain amino acid levels. Compared with the fat-fed control animals, WY 14,643-treated animals had raised plasma urea and ammonia levels as well as raised urine levels of N-methylnicotinamide and dimethylglycine. WY 14,643 induced changes in a number of key genes involved in amino acid metabolism in addition to expected effects on hepatic genes involved in lipid catabolism and ketone body formation. In conclusion, the present results suggest that, in rodents, effects of pharmacological PPARalpha activation extend beyond control of lipid metabolism to include important effects on whole body amino acid mobilization and hepatic amino acid metabolism.
过氧化物酶体增殖物激活受体α(PPARα)激动剂的特性主要体现在其对脂质和葡萄糖代谢的影响方面,而关于其对氨基酸代谢影响的报道却很少。我们研究了饱和脂肪饮食喂养的大鼠对PPARα激动剂WY 14,643(30微摩尔·千克⁻¹·天⁻¹,持续4周)的反应。用质子核磁共振分析血浆和尿液。使用高效液相色谱法测量血浆氨基酸,并通过DNA阵列评估肝脏基因表达。高脂饮食使血浆胰岛素和甘油三酯(TG)水平升高,而WY 14,643治疗改善了这种胰岛素抵抗和血脂异常,降低了血浆胰岛素和TG水平。此外,治疗减少了体重增加,但不改变累积食物摄入量,并增加了肝脏重量。WY 14,643使22种氨基酸中的12种血浆水平升高,包括生糖氨基酸和一些生酮氨基酸,而精氨酸显著降低。支链氨基酸水平没有改变。与脂肪喂养的对照动物相比,经WY 14,643治疗的动物血浆尿素和氨水平升高,尿液中N - 甲基烟酰胺和二甲基甘氨酸水平也升高。WY 14,643除了对参与脂质分解代谢和酮体形成的肝脏基因产生预期影响外,还诱导了许多参与氨基酸代谢的关键基因发生变化。总之,目前的结果表明,在啮齿动物中,药理学激活PPARα的作用不仅限于脂质代谢的控制,还包括对全身氨基酸动员和肝脏氨基酸代谢的重要影响。